Trial Profile

Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Ethyl eicosapentaenoic acid (Primary)
Indications Advanced breast cancer; Carcinoma; Inflammatory breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Jan 2024 Status changed from recruiting to discontinued due to poor accrual.
12 Apr 2022 Planned End Date changed from 30 Jun 2023 to 30 Jun 2026.
12 Apr 2022 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com